Evidence map›Paper›PMID 41090230›Full record

Trial reportHypertension (Dallas, Tex. : 1979)2025

Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy.

William B White, Richard J Kovacs, Jessica K Alexander, Christine Baranak, Deborah A Nichols, Douglas S Fuller, Jing Dai, Marisa Whalen, Akinyemi Ajayi, Barbara Hutchinson and 2 more

Registry-linked trialAbstract readClinical Trial, Phase IVComparative StudyMulticenter Study
In one paragraph

Trial report in Hypertension (Dallas, Tex. : 1979), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05869773 (An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to Xywav), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05869773 phase4completednot on this map

An Open-Label, Multicenter Switch Study Evaluating Changes in Blood Pressure in Participants With Narcolepsy Switching From High-Sodium Oxybate to Xywav

TypeinterventionalSponsorJazz PharmaceuticalsRan2023 to 2025Enrolled155ConditionsNarcolepsyArmsJZP258
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Reply to "Unexpectedly higher mortality in non‑type 1 narcolepsy: diagnostic heterogeneity or unmeasured confounders?"Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
    Article
  2. Review
  3. Review
  4. Unexpectedly higher mortality in non‑type 1 narcolepsy: diagnostic heterogeneity or unmeasured confounders?Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
    Article
  5. Mortality in narcolepsy and other sleep clinic patients: a 25-year propensity-matched VA cohort study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

William B WhiteCalhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.).ORCID 0000-0001-7310-8491
Richard J KovacsCalhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.).ORCID 0000-0003-0333-9168
Jessica K AlexanderJazz Pharmaceuticals, Palo Alto, CA (J.K.A., D.A.N., J.D., M.W.).
Christine BaranakJazz Pharmaceuticals, Philadelphia, PA (C.B., D.S.F.).
Deborah A NicholsJazz Pharmaceuticals, Palo Alto, CA (J.K.A., D.A.N., J.D., M.W.).ORCID 0009-0005-0886-1707
Douglas S FullerJazz Pharmaceuticals, Philadelphia, PA (C.B., D.S.F.).
Jing DaiJazz Pharmaceuticals, Palo Alto, CA (J.K.A., D.A.N., J.D., M.W.).ORCID 0009-0005-2360-3802
Marisa WhalenJazz Pharmaceuticals, Palo Alto, CA (J.K.A., D.A.N., J.D., M.W.).
Akinyemi AjayiChildren's Lung, Asthma and Sleep Specialists, Winter Park, FL (A.A.).
Barbara HutchinsonChesapeake Cardiac Care, Bowie, MD (B.H.).
Yves DauvilliersSleep-Wake Disorders Unit, Gui-de-Chauliac Hospital, CHU Montpellier, Institute of Neurosciences of Montpellier, University of Montpellier, France (Y.D.).ORCID 0000-0003-0683-6506
Virend K SomersDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (V.K.S.).ORCID 0000-0003-4045-4341

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeople with narcolepsy are at increased risk for hypertension and cardiovascular disease; excessive sodium intake is linked to both.

methodsWe studied patients with narcolepsy and office systolic blood pressures (BPs) of 130 to 155 mm Hg taking twice-nightly high-sodium oxybate for ≥6 weeks who switched to low-sodium oxybate at the same dosage. The primary end point was the change from baseline in mean 24-hour ambulatory systolic BP at the end of treatment (≈6 weeks after switching). Secondary and exploratory end points included changes in diastolic BP, office BP, and 24-hour sodium excretion.

resultsPatients (n=43) had a mean age of 45 years, were 65% female, 33% on antihypertensives, with baseline mean (SD) office BP of 138.0/85.2 (5.7/6.6). Mean (SD) total high- and low-sodium oxybate dosages of 8.0 (1.1) and 8.1 (1.1) g/night, respectively, represented 1456.5 (206.2) and 117.8 (16.3) mg of sodium. The median 24-hour urinary sodium was 4278 mg/d at baseline and 2703 mg/d at the end of treatment (median change, 1288 mg/d). Mean (SE) 24-hour ambulatory systolic BPs at baseline and study end were 132.3 (1.8) and 128.2 (1.8) mm Hg (least-squares mean change, -4.1 [95% CI, -6.9 to -1.4] mm Hg; 1-sided

conclusionsPeople with narcolepsy switching from high- to low-sodium oxybate showed substantially reduced daily medication-related sodium intake and significant 24-hour BP reductions. These results demonstrate the importance of reducing pharmaceutical sodium content in this elevated cardiovascular risk patient population. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05869773.

Indexed as

Blood PressureHypertensionNarcolepsySodium OxybateAdjuvants, AnesthesiaAdultBlood Pressure Monitoring, AmbulatoryDose-Response Relationship, DrugFemaleHumansMaleMiddle AgedTreatment OutcomeAdjuvants, AnesthesiaSodium Oxybateblood pressureheart disease risk factorshypertensionnarcolepsysodium oxybate

Identifiers

PMID41090230
PMCPMC12626475

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.